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Abstract
Kidney transplantation is the preferred treatment for patients with end-stage renal disease.
However, ischemia-reperfusion injury (IRI) is an inevitable consequence of renal
transplantation, with prolonged IRI periods associated with decreased graft survival and
function. We have previously demonstrated that the supplementation of University of
Wisconsin (UW) organ preservation solution with hydrogen sulfide (H2S) donor molecules,
such as AP39, leads to improved renal graft function and reduced transplantation-associated
IRI. However, the approval of these experimental donor drugs for clinical use may be years
away. In this study, we investigate the effects of an FDA-approved H2S donor molecule,
sodium thiosulfate (STS), to determine whether STS could mitigate cold renal IRI. In an in
vitro model of renal IRI, adding STS to serum free media improved cell viability for cold
preservation at 40C in a dose-dependent manner. Using a syngeneic renal transplantation
model, we investigate the effect of adding STS to University of Wisconsin (UW) preservation
solution, the clinical standard for preservation solution in static cold storage. Adding 150µM
STS to UW solution improves graft survival, urine output and serum creatinine and blood urea
nitrogen levels compared to preservation storage with UW solution alone.. Histopathological
examination reveals a reduction in apoptosis and acute tubular necrosis along with decreased
macrophage and neutrophil infiltration. Additionally, STS-supplemented preservation solution
induced mitochondrial biogenesis and reduced renal apoptosis and inflammation gene
expression. These data suggest that STS treatment on cold IRI-associated renal injury could
represent a novel clinically applicable strategy to minimize the detrimental outcomes of
prolonged cold IRI during renal transplantation.
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Summary for Lay Audience
Kidney transplantation is inherently associated with ischemia-reperfusion injury (IRI), a
biological event that causes tissue damage to the transplanted kidney organ. Current methods
to minimize IRI involves preserving the kidney in University of Wisconsin (UW) solution at
cold temperatures. However, this kidney preservation method has persisted in its most simple
form, as this method has not changed since its conception 60 years ago. Contrastingly, due to
its low supply, more kidneys with increased cold IRI times are being accepted and used for
transplantation to keep up with its high demand. Sodium thiosulfate (STS) is a clinical drug
used to treat patients with calciphylaxis and cyanide poisoning. In the past decade, numerous
studies have elucidated the protective effects of STS on hypertension and IRI on other organs,
such as liver, heart and brain. Here we sought to determine if STS plays a beneficial role in
minimizing cold IRI associated with kidney transplantation. We concluded that preservation
of renal grafts in STS-supplemented UW solution protects against prolonged IRI by
suppressing apoptotic and inflammatory pathways, and thereby improving graft function and
recipient survival. With STS being an FDA-approved compound, its protective benefits could
serve as a novel clinically applicable therapeutic strategy to mitigate the harmful outcomes of
prolonged IRI during kidney transplantation.
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Chapter 1

1

Introduction

1.1 End stage renal disease
End-stage renal disease (ESRD) is the last stage of chronic kidney disease (CKD)
after which the kidney is no longer able to support an individual’s day-to-day needs [1].
Patients with ESRD exhibit a glomerular filtration rate (GFR) of less than 15 mL/min, a
marker of significant kidney damage [1]. In North America, the most common causes of
CKD are diabetes, hypertension, and obstructive uropathy [1]. In 2019, ESRD affected
over 41,000 Canadians, a 33% increase since 2010 [2], and is therefore a major burden to
the healthcare system.
There are currently two forms of treatment for renal failure in ESRD patients:
dialysis and renal transplantation. Dialysis is a treatment for kidney failure by removing
waste, toxins, and excess fluids to prevent them from building up in one’s body while
maintaining a safe level of chemicals, such as sodium, potassium, and bicarbonate, in the
blood [3]. This process can be done by direct filtering of the blood through a dialysis
machine (hemodialysis) or a surgical implanted catheter in the abdomen filled with
dialysate to filter blood through the peritoneum via passive diffusion (peritoneal dialysis)
[4]. However, long term risks of dialysis include increased infections, anemia, low blood
pressure, and cardiovascular complications. The 10-year survival rates of patients with
ESRD in Canada undergoing dialysis are less than 15%, which is similar to other chronic
illnesses such as cancer [2]. Another treatment for ESRD is kidney transplantation, a
surgical procedure to procure a healthy kidney from a living or decreased donor and
subsequent engraftment of the kidney into a recipient. Compared to dialysis, kidney
transplantation is the treatment of choice for patients with ESRD as it offers improved
survival and quality of life. Patients who receive renal transplantation show a 79.8% 5-year
survival rate for deceased donors and 92.4% for living donors, compared to a 42.1%
survival for ESRD patients treated with dialysis alone [2]. Renal transplantation is also the
more cost-effective long-term treatment for ESRD, since the total annual cost per patient
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on dialysis is approximately $100,000 [4]. In addition, ESRD patients who received renal
transplantation displayed better quality of life compared to patients undergoing chronic
dialysis treatment due to the decreased cardiovascular complications, fewer dietary
restrictions, and the elimination of multiple visits per week to dialysis clinics for
hemodialysis [5]. Overall, it is evident that renal transplantation is a preferred choice for
the treatment of ESRD.

1.2 Obstacles for renal transplantation
1.2.1

Availability of Donor Organs
Although renal transplantation is the optimal choice for treating patients with

ESRD, the lack of available donor organs is a primary challenge that limits the
implementation of kidney transplantation to such patients. In the past decade, the demand
for kidney transplantation has increased due to prevalence of chronic diseases such as
hypertension and diabetes. As such during this period, the kidney transplantation waiting
lists have grown by 62% in the United States and 20% in Canada, with over 105,000
patients on the kidney transplantation wait list in North America [6,7]. On the other hand,
the total number of living kidney donors remains stagnant, with an average of 400 cases
per year in Canada [2]. This increase in demand over supply of living donor kidneys
increases mortality rates of ESRD patients as they are forced to undergo longer dialysis
periods while the transplantation waiting lists grows.

1.2.2

Ischemia reperfusion injury
Another major challenge in renal transplantation is that organ procurement is

inherently associated with ischemia-reperfusion injury (IRI). Renal IRI is an inevitable
consequence of transplantation and is defined as tissue injury due to temporary cessation
of blood flow upon procurement (ischemia) and subsequent restoration of blood flow to
the ischemic graft upon transplantation (reperfusion) [8]. The first major molecular event
of IRI occurs when cells are deprived of adequate oxygen due to cessation of blood flow,
resulting in energy depletion since the cells are unable to synthesize ATP [9]. The depletion
of ATP elicits a rise in inorganic phosphate and inhibits Na+/K+ pumps, resulting in influx
of Ca2+ in the cytoplasm, and increased mitochondrial inner membrane permeability [10].
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In addition, prolonged ischemic time can damage multiple protein complexes in the
electron transport chain (ETC), ultimately leading it to be more prone to electron leakage
[11]. The second major molecular event in IRI occurs when blood flow is restored to the
ischemic tissue and is often characterized by increased ROS formation due to
mitochondrial complex I dysfunction and decreased ATP production and cell death [12].
ROS can impair ETC complexes, which further inhibits ATP production and increases
electron leakage [13]. Cellular ATP depletion leads to an increase in expression of proapoptotic proteins such as BID and BAX, which causes mitochondrial swelling and induces
the efflux of cytochrome c and apoptosis-inducing factor [14]. Correspondingly, these
factors activate caspase 3 apoptotic signaling cascades, which initiates cellular apoptosis.
The pathophysiology of IRI in the kidney also involves the triggering of inflammation
cascades that damages renal tissue. Activation of Janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathway can recruit pro-inflammatory cytokines
such as tumor necrosis factor alpha (TNFα) and interleukin 6 (IL6), all of which plays a
major role in renal damage induced by IRI [15-18]. Additionally, these inflammatory
mediators and ROS elicit leukocytes and neutrophil infiltration into the ischemic tissue,
which leads to swelling of the endothelial cell and promotes programmed necrosis [19-21].
Kaminski et al. showed that activation of neutrophils can release ROS and other mediators
that accelerates IRI, ultimately leading to acute and chronic kidney failure [22]. Recent
studies found a new type of programmed cell death that is closely related to the
pathophysiological process of IRI: ferroptosis [23]. Ferroptosis is characterized by large
amount of iron accumulation, intracellular lipid ROS, and lipid peroxidation during the
iron-dependent cell death process [24]. A study in 2014 found that ferroptosis was
functionally relevant in IRI and acute tubular necrosis and showed that a ferroptosis
inhibitor protected against this injury [25]. Another study highlights ferroptosis as the main
death pathway of renal tubular cells in an acute kidney injury mouse model [26]. An
additional mode of regulated programmed cell death is necroptosis, whose pathway is
characterized by TNFα, interferon, Fas ligands, and oxidative stress [27]. Recent studies
found that renal IRI led to increased levels of necroptosis in human kidney cells, as evident
by the upregulation of necroptotic markers including oxidative stress, inflammatory
cytokines, MLKL, RIPK1, and RIPK3 [28]. Interestingly, an in vivo study found that
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apoptosis co-occurred with necroptosis in mice following renal IRI, as shown by increased
levels of cleaved caspase 3 and positive TUNEL cells [29]. The pathophysiology of renal
IRI is very complex but some pathological pathways such as excessive ROS production,
ATP depletion, induction of cellular apoptotic pathways, activation of neutrophils, and
other inflammatory mediators are major molecular events associated with IRI. These
complex processes are graphically depicted in Figure 1.

1.3 Current clinically used methods of organ preservation in
renal transplantation
During renal transplantation, the ischemic period is divided into warm ischemic time
(WIT) and cold ischemic time (CIT) [30]. The former is defined as the loss of blood flow
to the organ which occurs when the renal arteries and veins are ligated. This interval of
warm ischemia is then followed by a period of cold ischemia of various time periods
wherein the organ is conserved in a hypothermic solution at 4⸰C to slow cellular activity
and reduce production of toxic metabolites before being transplanted into the recipient [3132]. By slowing down the harmful effects of IRI during CIT, physicians can accomplish
tissue typing and cross-matching as well as organ transportation and preparation of the
recipient [33]. Immunosuppressive regimens have advanced substantially in recent years
along with our understanding of allograft rejection, yet organ preservation persists in its
most simple form; static cold storage (SCS) is the most prevalent method for renal allograft
preservation and this method has not changed since its conception over 60 years ago [34].
Although SCS is the current standard of care for organ preservation, these methods have
been maximized and prolonged periods (>24h) of cold IRI are still associated with
increased rates of acute tubular necrosis, decreased graft survival, and delayed graft
function [35-38]. In recent years, we have seen a shift away from the traditional paradigm
of SCS to a more dynamic organ storage, such as the use of machine perfusion (MP).
Traditionally, SCS organs are bathed in preservation solution inside sterile plastic bags
covered with ice prior to transportation to the recipient. MP, on the other hand, is a pump
that continuously perfuses the kidney with preservation solution [39]. Immediately after
procurement, the organ is attached to the machine via the renal artery, and a device
generates a continuous flow via a peristaltic pump [39]. Studies that compared MP to SCS
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Figure 1: Pathophysiology of kidney ischemia reperfusion injury during
transplantation. Renal IRI is an inevitable obstacle of transplantation and is defined as
tissue injury due to temporary cessation of blood flow upon procurement (ischemia) and
subsequent restoration of blood flow to the ischemic tissue upon transplantation
(reperfusion). This process increases mitochondrial permeability and decreases ATP
levels, resulting in an increase in ROS production. In addition, the metabolic deficit triggers
pro-apoptotic markers BAX, ultimately leading to apoptosis via the complement pathway.
ROS and DAMPs can also trigger inflammatory cytokines and consequently cause innate
immune cells to adhere to inflamed renal endothelium and extravasate to the interstitial
space, where they release more damaging ROS. These renal injuries resulting from IRI
results in renal cell death and graft dysfunction in the post-transplant period.
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have shown that MP kidneys had lower incidence of delayed graft function, while
providing additional parameters, including flow, temperature, and pressure, that allow a
more elaborate evaluation of ischemic damage and organ viability to predict post-transplant
outcomes [40-43]. Often, transplant centers differ in the timing and nature of MP utilized
in terms of its availability and transportability. Therefore, MP is frequently combined with
periods of SCS, making a debate on what the ideal perfusion period and timing of perfusion
are [44]. An additional potential use of MP for surgeons is the assessment of graft quality
and viability prior to transplantation through the analysis of perfusion flow and quantifiable
biomarkers within the perfusate [45-46].
Currently, the most commonly used organ preservation solutions for kidney
transplantation are University of Wisconsin (UW) solution, histidine-tryptophanketoglutarate (HTK), Celsior, and hyperosmolar citrate (Marshall’s solution, HOC) [33].
Out of the listed solutions, UW solution is currently considered to be the gold standard
among organ preservation solutions. UW solution was developed by Dr. Belzer and James
Southard in the 1980s and was shown to safely allow preservation of human grafts for an
extended period [47]. UW solution is made up of a combination of metabolically inert
substrates, including raffinose, adenosine, glutathione, allopurinol, hydroxyethyl starch,
and lactobionate [48]. In addition, UW solution contains adenosine, which acts as the
substrate for the synthesis of ATP during reperfusion and the antioxidant glutathione to act
as oxygen radical scavengers and neutralize ROS generated during the reoxygenation part
of reperfusion. [35,48]. However, some of the disadvantages to the solution are its high
viscosity and high potassium concentration, making it less efficient in quickly flushing a
donor graft. HTK was used as an alternative solution based on its low viscosity, low
potassium level, and lower cost compared with those of UW solution [49]. Studies
comparing the use of UW and HTK for organ preservation have shown similar results in
terms of graft and the patient survival, especially if CIT was kept at a minimum [49-52].
However, in studies with prolonged CIT, HTK was shown to be inferior compared to UW
due to increased risk of graft loss and thrombosis [51-54]. To keep up with the global rising
incidence of ESRD and ever-increasing number of patients on transplant waitlists, many
transplant programs accept grafts with extended cold storage times, thus increasing CIT
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which ultimately continues to represent a major challenge in mitigating renal IRI and
improving clinical outcomes of transplantation.

1.4 Hydrogen Sulfide
One recent promising therapeutic strategy to mitigate IRI during renal
transplantation is the use of gasotransmitters. Gasotransmitters are small, endogenously
produced molecules and have been shown to have various cytoprotective effects. The
family of molecules includes carbon monoxide (CO), nitric oxide (NO), and hydrogen
sulfide (H2S). H2S is a gasotransmitter that is endogenously produced from the amino acid
L-cysteine and 3-mercaptopruvate via 3 enzymes: cystathionine β-synthase, cystathionine
γ-lyase, and 3-mercaptopruvate sulfurtransferase [55]. For several decades, H2S was
notoriously known for its toxic effects and death among agricultural and industrial workers
at high concentrations. The mechanism underlying the toxic effect of H2S involves
inhibition of cytochrome c oxidase (complex IV), the terminal complex of the
mitochondrial electron transport chain, resulting in lack of oxygen use in cells [56]. In the
past 25 years, however, this obnoxious-smelling membrane-permeable gas has risen above
its negative public image and is now known to play several important functions in
physiological processes at low concentrations. In addition to its many cellular signaling
properties such as reducing inflammation and stimulating cell proliferation, H2S can also
play a detoxifying role during oxidative stress by increasing the development of the
antioxidant glutathione [57]. Furthermore, a 2012 study by Aminzadeh et al, found that
progression of chronic kidney disease is associated with a reduction of H2S and its
corresponding production enzymes [58]. Given the cytoprotective features of H2S, its
supplementation with preservation solution could contribute to combatting the
inflammatory and oxidative stress environment that IRI induces. H2S can be delivered via
gaseous administration or through the use of donor molecules. Our lab has been the first to
show that supplementing standard organ preservation solution (UW solution) with H2S
donor molecules (AP39 and GYY147) protects rats and porcine donor kidneys from
prolonged warm and cold ischemic injury and improves graft function following
transplantation [59-61]. In terms of alleviating the effects of IRI, AP39 demonstrates
greater potential because it is targeted to the mitochondria, which has been well established
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as a key mediator in IRI, via its triphenylphosphonium motif. Further evidence of this was
confirmed using an in vitro model of renal IRI, where it was shown that AP39 is 1000-fold
more cytoprotective from cell death than non-targeting H2S donor molecules, such as
GYY4137 [62]. We have also shown that prolonged SCS in UW solution supplemented
with AP39 leads to improved graft function and reduced tissue injury following allogeneic
renal transplantation in rats [63]. These latest findings have pushed the potential clinical
use of H2S donor molecules, especially those targeting the mitochondria, in organ
preservation solutions. Unfortunately, these experimental H2S donor molecules are
decades away from clinical use due to the time-consuming process of clinical testing.
Therefore, to translate our bench work to clinical practice, we have begun looking into
sodium thiosulfate (STS), an already clinically utilized drug known to release H2S [64].

1.5 Sodium Thiosulfate
Sodium thiosulfate (STS, Na2S2O3) is a synthetic, white crystalline solid or powder
with no odor and dissolves easily in water. This inorganic compound is typically available
in the form of the pentahydrate (Na2S2O3·5H2O), with a molecular weight of 158.11g/mol.
STS is currently on the World Health Organization’s list of essential medicines and has
numerous other uses including a common food preservation additive, a water dechlorinator,
a photographic fixative, and a bleaching agent for paper pulp.

1.5.1

Contemporary uses of STS
STS has long been known to physicians as STS was used to treat some rare medical

conditions, including cyanide poisoning, cisplatin toxicity, and calciphylaxis. Over the past
few decades, STS has been used as an antidote for the treatment of cyanide poisoning. STS
was shown to serve as a sulfur donor in the reaction catalyzed by rhodanese for
detoxification of cyanide to thiocyanate, which is then renally excreted [65]. This occurs
after sodium nitrate removes cyanide from the mitochondrial electron transport chain by
inducing the formation of methemoglobin [65,66]. The United States has a standard
cyanide antidote kit which first uses 10 mL intravenous sodium nitrite, followed
immediately by 50 mL (250 mg/mL) intravenous STS.
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Another STS use is to protect against cisplatin toxicity. Cisplatin is one of the most
widely used agents to treat solid tumors. However, it has adverse effects on renal,
neurological, and hematological systems [67]. Laplace et al. showed that administering
STS protects renal impairment following cisplatin chemotherapy [68]. Efficacy is thought
to be related to STS binding to free platinum, resulting in total clearance of inactive
metabolite and limiting renal tubular cell necrosis [69]. In addition, the use of cisplatin to
effectively treat childhood hepatoblastoma can cause severe and permanent ototoxicity,
leading to eventual hearing loss. Studies concluded that addition of STS six hours after
cisplatin chemotherapy resulted in lower incidence of cisplatin-induced hearing loss among
children with standard-risk hepatoblastoma, without jeopardizing overall and event-free
survival [70]. STS was shown to inhibit oxidative stress at the sensitive cochlea that was
caused by ototoxicity. After two successful clinical trials, Fennec Pharmaceuticals is
currently waiting on FDA approval on the first potential prevention of platinum induced
ototoxicity in pediatric patients [71].
Calciphylaxis is yet another condition where STS is used for treatment. Seen in
people with ESRD, calciphylaxis is predictor of cardiovascular death in long-term
hemodialysis patients [72]. It is characterized by systemic medial calcification of the
arterioles leading to ischemia and subcutaneous necrosis. Promising results have been
obtained through the use of intralesional STS. Areas of clinically active disease were
treated with 250ml/mg STS, resulting in the resolution of calciphylaxis lesions over a
period of weeks with no recurrence of the disease [73]. Recently, Peng et al. conducted a
systemic review of several cases on the use of STS for calciphylaxis and found that STS
has a promising role as an effective therapy for calciphylaxis by acting as an anticalcification agent with vasodilatory and antioxidant properties [74]. Their study results
supported previous reports that suggested STS could combine with insoluble tissue calcium
salts to form calcium thiosulfate, a salt that can later be dialyzed [74-76].
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1.5.2

Biochemical characteristics of STS and its relationship to
H 2S

At a physiological level in tissue, thiosulfate can be generated from the mitochondrial
sulfide oxidation pathway with H2S as the substrate. This process involves 3 mitochondrial
enzymes: quinone oxidoreductase, sulfur transferase, and sulfur dioxygenase [77]. Using
an isolated mitochondria rat model, Hildebrandt et al. showed a potential biochemical
pathway of H2S oxidation to thiosulfate [78]. First a membrane bound sulfide, quinone
oxidoreductase (SQR), oxidizes H2S to persulfide, which is transferred to a persulfide
group (SQR-SSH). A persulfide dioxygenase (PDO) in the mitochondrial matrix oxides
one persulfide molecule to sulfite (H2SO3), which is then used in a sulfurtransferase
reaction catalyzed by rhodanese (Rhd) to form thiosulfate [77]. Rhodanese is a
mitochondrial enzyme that transfers sulfur atom from sulfane-containing donor to
thiophilic acceptor substrate [79]. Catalytic activity of rhodanese occurs by a double
displacement mechanism, where the active site cysteine residue (Cys247) accepts a sulfur
atom from the persulfide intermediate state followed by the transfer of sulfide sulfur from
enzyme to the nucleophilic acceptor sulfite to produce thiosulfate [80]. Although human
mitochondria also utilize sulfide oxidation pathway, recent evidence suggests that the
persulfide intermediate formed by human SQR uses glutathione (GSH) [81, 82]. More
recently, Libiad et al. found that the kinetic behavior of these enzymes favors SQR using
glutathione as an acceptor to form glutathione persulfide (GSSH), which is then converted
to thiosulfate by human rhodanese [83]. This is further confirmed by kinetic simulations in
previous rat liver mitochondria studies in the absence and presence of GSH, which supports
that glutathione persulfide is the first intermediate formed in the flow of the sulfide
oxidation pathway [82]. This complex process is graphically depicted in Figure 2.
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SQR – sulfide quinone
oxidoreductase
CIII/CIV – mitochondrial
electron transport
complexes 3 and 4
SO – sulfite oxidase
MST-mercaptopyruvate
sulfurtransferase
GSH- glutathione
PDO- persulfide
dioxygenase
Rhd – Rhodanase

Figure 2: Mitochondrial sulfide oxidation pathway generates thiosulfate from H2S.
Hydrogen sulfide (H2S) is produced by enzymes of the trans-sulfuration pathway,
cystathione γ-lyase (CSE), and cystathionine β-synthase (CBS). A third enzyme, 3mercaptopyruvate sulfurtransferase (MST) can also produce endogenous H2S in the
presence of the substrate 3-mercaptopyruvate. A membrane bound sulfide, quinone
oxidoreductase (SQR), oxidizes H2S to persulfide, which is transferred to a glutathione
(GSH). A persulfide dioxygenase (PDO) in the mitochondrial matrix oxides one
glutathione persulfide (GSSH) to sulfite (H2SO3), which is then used in a sulfurtransferase
reaction catalyzed by rhodanase (Rhd) to form thiosulfate (S2O32-) by transferring a second
glutathione persulfide from SQR to sulfite. Sulfite can be further oxidized by sulfite
oxidase (SO) to form sulfate and is subsequently excreted in the urine.
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In addition to the generation of thiosulfate from H2S via the sulfide oxidation
pathway, the reverse reaction can also occur in the mitochondria. Jackson et al. [81], using
recombinant human SQR in Escherichia coli, showed that the metabolism of thiosulfate is
catalyzed by thiosulfate reductase as it consumes two glutathione and results in the
generation of sulfite, oxidized glutathione, and H2S. Further evidence of thiosulfate’s
ability to produce H2S via a glutathione-dependent reduction was confirmed in a study that
showed exogenous thiosulfate treatment effects sulfide levels in a dose dependent manner
that impacts glutathione metabolism [84]. On the other hand, other studies do not support
the contribution of glutathione in H2S production from thiosulfate. Olson et al. found that
H2S generation from thiosulfate was due to the presence of DTT, an exogenous reducing
agent [85]. However, regardless of the exact mechanism of how sulfur is transferred,
thiosulfate appears to be a key intermediate. In addition to thiosulfate being a stable,
nontoxic metabolite of H2S [86], it is also a sulfane sulfur which is defined as sulfur atoms
covalently bonded to other sulfur atoms, making it unstable and readily oxidizing in air and
reducing with thiols [87]. Compounds containing sulfane sulfur are known to possess cell
regulatory effects through the activation or inactivation of enzymes and changing protein
activities [88]. The functions of sulfane sulfur include tRNA sulfuration, antioxidant
regulation, and iron-sulfur protein formation [88-90].

1.5.3

Protective roles of STS
STS has shown some promise in treating other conditions by serving as a H2S donor

molecule. Thiosulfate has two unpaired electrons: one at the single bonded sulfur moiety
of the disulfide bond, and the other at the single bonded oxygen [91]. This characteristic
allows thiosulfate to donate electrons to unpaired damaging electrons associated with
reactive oxygen species (ROS), making it an effective antioxidant [85, 92, 93]. Further
evidence of thiosulfate’s antioxidant properties was confirmed in a mouse model of
congestive heart failure study by Sen et al., where their data showed that thiosulfate
scavenged superoxide in myocardial tissue [94]. Mishanina et al. took a step further and
discovered that thiosulfate can react with superoxide to form glutathione, a thiol-dependent
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antioxidant system in mammalian cells [95]. Further evidence of STS’s antioxidant
properties was confirmed in both in vitro and in vivo models of hyperoxaluria and renal
injury, where the authors showed that STS treatment scavenged reactive oxygen species in
a dose dependent manner and maintained superoxide dismutase activity in order to reduce
cellular hydrogen peroxide levels [96]. A recent study examined the protective properties
of STS in angiotensin II-induced renal hypertension in rats where the authors showed that
STS treatment induced a lower plasma urea, proteinuria, and improved creatinine clearance
[97]. In addition, STS prevented angiotensin II-induced influx of macrophages,
demonstrating its anti-inflammatory properties [97]. Their study results agreed with
previous reports which demonstrated that suggested H2S has anti-inflammatory capabilities
by down-regulating expression of inflammatory genes such as IL-1β, TNF-α, and MAP-1,
and by reducing macrophage recruitment [98].

1.5.4

Physiological roles of STS in IRI
It has been well recognized that mitochondrial damage and its ensuing dysfunction

is a key mediator of IRI. Under ischemic and oxidative conditions, mitochondrial
permeability transition pore (mPTP) opens, leading to mitochondrial dysfunction and
ultimately cell death [99]. However, a recent study by Baldev et al. developed an in vivo
model where rats were induced with nephrolithiasis by administrating ethylene glycol
[100]. STS treatment group demonstrated normal renal tissue form, along with normal urea
and serum creatinine. STS was found to activate mitochondrial ATP-sensitive potassium
(KATP) channel, suggesting that the opening of these channels may have inhibited
mitochondrial permeability transition [94,101]. Further evidence of STS maintaining
mitochondrial function was confirmed in a study by Mohan et al., where isolated rat
mitochondria were subjected to physiological oxidative stress. The results showed that the
pretreated STS group had higher renal mitochondrial enzyme activity due to its increased
NADH dehydrogenase activity compared to the non-treated group [102]. In a recent study,
Ravindran et al. reported that a rat heart IRI model preconditioned with STS exhibited
similar ATP synthase activity and mitochondrial enzyme activity compared to sham [103].
In addition, the STS treatment group improved activities of ETC complex enzymes I-IV
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and showed significantly increased expression of PGC-1α, a positive regulator of
mitochondrial biogenesis, ATP production, and ROS-detoxifying system [104].
A 2017 study showed that in both in vitro and in vivo models of heart IRI, STS
preconditioning significantly increased NADH dehydrogenase activity and decreased
oxidative stress due to increased activities of antioxidant enzymes such as GSH, catalase,
and superoxide dismutase [105]. In addition, an in silico model in the same study showed
that STS has higher binding affinity for caspase 3. Once STS interacts with caspase 3 and
binds to its Cys-163 active site via strong hydrogen bonds, it increases persulfidation of
the enzyme. This oxidation reaction results in the inactivation of caspase-3 by preventing
access of natural substrate to caspase-3 binding site, ultimately halting apoptosis [105].
Further evidence of STS’s higher binding affinity for caspase 3 was confirmed in a study
by Marutani et al., where the authors discovered that STS inhibits caspase 3 via
persulfidation of the same active site Cys-163 to protect the mice against neuronal IRI
[106]. In addition, STS was shown to activate Erk 1/2 and block the c-jun N-terminal kinase
(JNK), which lead to the inhibition of apoptosis by preventing the dephosphorylation of
the pro-apoptotic protein Bad and the downregulation of antiapoptotic gene, Bcl-2 [107109]. In summary, the literature suggested that STS modulates mitochondria potassium
ATP channel, possess a calcium chelation effect, mitigates oxidative stresses, has antiinflammatory properties, involves in mitochondrial ETC regulation, and acts as a sulfide
donor, ultimately leading to protection against IRI in various tissues.

1.5.5

Rationale and Hypothesis
We have previously shown that supplementing standard organ preservation

solution (UW solution) with H2S donor molecules (AP39 and GYY147) protects rats and
porcine donor kidneys from prolonged warm and cold ischemic injury and improves graft
function following transplantation [59,61-63]. However, it is important to note that these
H2S donor molecules, such as AP39, must go through many regulatory steps before they
could be available for clinical use. STS on the other hand is an FDA-approved compound
for treating diseases such as calciphylaxis and cyanide poisoning [64-68]. In addition,
several studies have elucidated the ability of mitochondrial enzymes to generate STS from
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H2S via a sulfide oxidation pathway and the reverse reaction via a glutathione-dependent
reduction [77-78]. Emerging data on the biological effects of STS and its close chemical
relationship with H2S support the development of STS-based therapeutics.
Besides its clinical applications, STS has also been shown experimentally to effectively
protect against renovascular hypertension, and other models of renal injury via its
antioxidant and anti-inflammatory properties [95,97,98]. Additionally, numerous studies
suggested that STS can mitigate IRI-induced damage in heart and brain tissues by
preserving mitochondrial complex, modulating mitochondrial ATP channel, mitigating
oxidative stress, and downregulating pro-apoptotic genes [99-104].
In the context of kidney transplantation, modification of the preservation solutions with
STS at the right concentration may be a simple, inexpensive, and nontoxic novel
therapeutic strategy to mitigate prolonged cold renal IRI in donor organs to ultimately
improve renal graft outcomes and minimize post-transplant complications. However, this
novel concept remains to be explored in a clinically relevant model of renal transplantation.
HYPOTHESIS: Supplementation of standard organ preservation solutions with STS will
lead to improved graft function and decreased tissue injury in an in vitro and in vivo rat
transplantation model by limiting IRI-induced oxidative stress and by preserving cellular
metabolic activity.

1.6 Aims and Objectives
The objective of this study was to elucidate the protective effects of STS organ preservation
in cellular and rat models of renal IRI. This study could ultimately help identify STS as a
novel therapeutic target for treatment of IRI associated with kidney transplantation.
The specific aims of the work outlined in this thesis were to: 1) Characterize underlying
mechanisms of cytoprotective effects of STS during renal IRI in vitro using rat kidney
epithelial (NRK-52E) cell lines; and, 2) Investigate whether STS improves graft function
and reduces tissue injury in an in vivo model of rat kidney transplantation.
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Chapter 2

2

Materials and Methods

2.1 In vitro model of renal epithelial cell IRI
An in vitro model of cold hypoxia and warm reoxygenation injury that mimics cellular
conditions during in vivo cold IRI was used to assess the protective effects of STS during
renal IRI. Rat kidney epithelial cells (NRK-52E cell line; ATCC, USA) were used in the
in vitro experiments because these cells are susceptible to ischemic injury [42] and used
for consistency with the rat in vivo transplantation model used for the second aim of this
study. The cells were cultured in Dulbecco’s modiﬁed eagle medium (DMEM) containing
10% fetal bovine serum (FBS) inactivated by heat at 600C for 20min and 1%
penicillin/streptomycin (P/S). Cells were incubated at normal growth conditions of 370C,
21% O2, and 5% CO2. During experimentation, control cells were in conditions identical
to those for pre-experimental cells. Experimental cells were treated with either serum free
media (SF), SF plus 200nM AP39, or SF plus varying concentrations of sodium thiosulfate
pentahydrate (STS), which were obtained from a 250mg/ml injectable solution of STS
(Seacalphyx® [Seaford Pharmaceuticals Inc, Mississauga, ON, Canada]). 200nM AP39
was used because they previously have shown to be cytoprotective against the same cell
line in a similar model of cold IRI [62]. Cells were then incubated at 100C for 24h in
hypoxic growth conditions (5% CO2, 0.5% O2, 95% N2) to simulate ischemic during cold
organ preservation conditions. These hypoxic conditions were created using
HypOxystation H85 hypoxia chamber (HYPO2YGEN, USA). 100C was used for the
hypothermic condition because this was the lowest temperature that could be
technologically achieved while maintaining a hypoxic 0.5% O2 level. Following hypoxia,
experimental cells media was replaced with control media and were reoxygenated via
incubation in normal growth conditions (370C, 21% O2, and 5% CO2) for 24h to simulate
reperfusion and associated injury.
Following 24h reoxygenation, cellular viability was assessed via staining of cells with
FITC-conjugated

Annexin-V

(FITC-Annexin-V;

BioLegend,

USA)

and

7-

Aminoactinomycin D (7-AAD; BioLegend, USA), which measures cellular apoptosis and
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necrosis, respectively. Cells were analyzed via flow cytometry using the CytoFLEX S
(Beckman Coulter, USA) and FlowJo version 11 (FlowJo LLC, USA) was used to
appropriately gate the data for statistical analysis.

2.2 Animal description and care
2.2.1

Experimental animals

Male Lewis rats were purchased from Charles River Canada (St. Constant, QC, Canada)
and used at 250-300g (n= 30). Rats were maintained in the Animal Care and Veterinary
Services facility at Western University (London, ON) under standard conditions. Animal
studies were approved by the Western University Council on Animal Care and Animal
Use.

2.2.2

Syngeneic renal transplantation surgical procedure and
postoperative monitoring of rats

Syngeneic Lewis rat renal transplantation was performed to eliminate any confounding
effects of immunosuppression. Rats were randomized into treatment groups, anaesthetized
with ketamine (30 mg/kg) and maintained under anesthesia with isoflurane during surgery.
Using aseptic techniques, the left donor kidneys were procured and flushed with a 28-G
Angiocath Becton-Dickinson with 10mL of either cold (40C) University of Wisconsin (IW)
preservation solution (UW group, n=8), or cold UW plus sodium thiosulfate pentahydrate
(150uM Seacalphyx® [Seaford Pharmaceuticals Inc, Mississauga, ON, Canada]; STS
group, n=6) until venous effluent was clear. Grafts were then placed in 50mL of the same
perfusion solution and stored at 40C for 24h, a period that has previously been shown to
result in acute tubular necrosis and inflammation that lead to graft loss and only 5%
survival at POD 3 rats treated with UW solution alone [59]. After undergoing bilateral
nephrectomy, recipient rats underwent renal transplantation with donor kidneys removed
from cold storage via end-to-side anastomosis of donor inferior vena cava to recipient
inferior vena cava with 11-0 Prolene suture followed by the donor ureter being
anastomosed to recipient ureter using 10-0 PDS sutures. Our aim was to assess the
protective effects of STS on graft function and survival after extreme cold storage in a
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survival model where the recipient rat was solely dependent upon the transplanted graft for
renal function. Sham-operated rats (mid-line incision only; n=5), were also followed to
establish a baseline for survival, histological analysis, BUN, and serum creatinine.
Additionally, another subset of rats in the STS group had grafts removed pre-emptively at
POD 3 (n=5) for comparison of histological analysis to UW animals that were sacrificed
at this time point. All surgeries were performed by the same microsurgeon who was blinded
to the experimental design with the length of surgery for the recipient being approximately
2-3h for both treatment groups. There was no difference in operating times between the
UW and STS treatment groups. Graft failure was presumed in animals that required
premature sacrifice (severe visible distress and/or >20% weight loss) or death. At the time
of sacrifice, all anastomoses were checked for surgical complications that may cause
variations in the results; none were discovered. The experimental model is graphically
depicted in Figure 3.

2.3 Creatinine and urine assays
Following renal transplantation, rats were monitored in metabolic cages for a period of 14
days or until sacrifice. The time period of 14 days was picked since animals that survived
past 9 days post-transplant were seen to have fully recovered renal function [59,61,62.63].
At various time points (POD 3, 5, 7, 10, and 14) rats were removed from their metabolic
cages and the previous 24h worth of urine output were measured and collected for urine
osmolality analysis. In addition, 200uL of blood was taken from the tail vein following the
ACVS protocol, spun at 2500rpm for 10min to separate the serum and stored at -800C until
analyzed for serum creatinine and BUN levels. Blood urea nitrogen and creatinine and
levels of serum obtained from renal transplantation and Sham-operated rats were
determined using the enzymatic method performed on the IDEXX Catalyst One Chemistry
Analyzer machine (IDEXX, Markham, ON). Urine osmolality levels were determined by
freezing-point osmometry using the 3320 Osmometer machine (Advanced Instruments,
Norwood, MA) and compared to company provided standards.
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Figure 3: Renal transplantation model in rats.
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2.4 Histological staining
In each arm of the study, renal grafts obtained at time of sacriﬁce were sagitally bivalved,
where half of the sagitally bivalved kidneys was placed in 10% formalin for paraffin
embedding and sectioning, while the other half was flash-frozen in liquid nitrogen and
stored at -800C for quantitative PCR (qPCR) analysis. Histological sections were stained
with Hematoxylin and Eosin (H&E) and Terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) to determine the level of acute tubular necrosis and apoptosis
respectively. H&E sections were assigned a score for ATN by a blinded renal pathologist
as per the following scheme: 1 = <11%, 2 = 11-24%, 3 = 25-45%, 4 = 46-75%, 5= >75%
graft ATN. Histological sections also underwent immunohistochemical staining, with n=5
for each treatment group. Sections were incubated with antibodies against kidney injury
marker (KIM-1), macrophage surface marker CD68, and neutrophil-specific enzyme
myeloperoxidase (MPO; Abcam®, Toronto, Canada) and visualized with secondary
antibodies and DAB substrate chromogen using the Dako Envision System (Dako,
Glostrup, Denmark) as per manufacturer’s protocol.

2.5 Microscopic image analysis
TUNEL and immunohistochemically stained sections were analyzed using an Eclipse 90i
digital light microscope at 10x magnification (Nikon® Instruments, New York) and were
read by a trained renal pathologist who was blinded to the treatment groups. Five images
were analyzed per section of TUNEL, KIM-1, CD68, and MPO analysis and total (+)
staining per field of view was quantified by ImageJ software v. 1.8 (National Institutes of
Health, Bethesda, MD).

2.6 Quantitative PCR analysis
Homogenized renal graft tissue obtained at POD 3, containing equal portions of cortex and
medulla, was analyzed to determine relative expression levels of genes of interest using
qPCR, with n=5 for each treatment group and Sham-operated rats. Renal tissues stored at
-800C were thawed and then immediately homogenized with a mechanical homogenizer.
Total RNA was isolated using RNeasy® Mini Kit (Qiagen, Toronto, Canada) and reverse
transcribed into cDNA using OneScript® Plus cDNA synthesis Kit (ABM, Canada) in
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conjunction with oligo(dT)12-18 primers as per manufacturer protocol. Isolated RNA were
analysed via nanodrop (DeNovix DS-11 Spectrophotometer, Canada) before use, with
A260/280 ratings consistently > 1.95 and > 1.8 respectively. The reaction mixture of each
qPCR sample had a volume of 20uL and was made as per Blastaq® Green 2X qPCR Master
Mix (ABM, Canada) protocol and analyzed using CFX Connect Real-Time PCR Detection
System machine (Bio-Rad, Canada). Primer sequences were designed using PrimerBLAST software (NCBI) against beta-actin, poly [ADP-ribose] polymerase 1 (PARP1),
interferon gamma (IFN-y), tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), Bcell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (BAX), caspase 3, BH3 interactingdomain death agonist (BID), c-Jun N-terminal kinase 1/2 (JNK1/2), peroxisome
proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1α), mitochondria
complex I (NDUFB8), mitochondria complex II (SDHB), mitogen-activated protein kinase
1/2 (ERK1/2), nuclear factor-erythroid factor 2 (Nrf2), lipocalin-2 (NGAL), and kidney
injury molecule-1 (KIM-1) genes are shown in Table 1. All genes of interest were
normalized against beta-actin. Fold changes of gene expression were compared to Shamoperated rats and were calculated using the ΔΔCt method.

2.7 Statistical analysis
Survival data were analysed using Kaplan-Meier survival analysis and all other data were
analysed using one-way ANOVA followed by Tukey’s post-hoc test performed using the
GraphPad (La Jolla, CA) Prism statistical software package, version 9.0. Statistical
significance was accepted at p < 0.05.
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Table 1. List of qPCR primer sequences
Primer

Sequence (5’

3’)

β-actin Forward

CCGCGAGTACAACCTTCTTG

β-actin Reverse

CGTCATCCATGGCGAACTGG

PARP Forward

TTGACTATGGCCAGGACGAA

PARP Reverse

CCAAAGTCATGGGGGATGAG

IFN- γ Forward

AGTTCGAGGTGAACAACCCACAG

IFN- γ Reverse

ATCAGCACCGACTCCTTTTCCG

TNF- α Forward

TTCGGGGTGATCGGTCCCAAC

TNF- α Reverse

TGGTGGTTTGCTACGACGTGG

IL-6 Forward

TTTCTCTCCGCAAGAGACTTC

IL-6 Reverse

GGTCTGTTGTGGGTGGTATC

BCL-2 Forward

TCATGTGTGTGGAGAGCGTC

BCL-2 Reverse

AGTTCCACAAAGGCATCCCAG

BAX Forward

CGTCTGCGGGGAGTCAC

BAX Reverse

CGATCCTGGATGAAACCCTGT

Caspase-3 Forward

GAGCTTGGAACGCGAAGAAA

Caspase-3 Reverse

GCCCATTTCAGGGTAATCCA

BID Forward

TGTCGGTCGGCAAACCTCTG

BID Reverse

GCCATTGCTGACCTCAGAGTCC
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JNK1 Forward

AGCCGGCCATTTCAGAATCA

JNK1 Reverse

CTCTCGCCTGACTGGCTTTA

JNK2 Forward

CAAGGAATTGTTTGTGCTGCTT

JNK2 Reverse

ACAGGACTTTATGGAGGACCA

PGC-1α Forward

GAGGGACGAATACCGCAGAG

PGC-1α Reverse

CTCTCAGTTCTGTCCGCGTT

NDUFB8 Forward

GGAGAGCCTTCCACATGACC

NDUFB8 Reverse

ATCTGGGTACGGCTCGTAGT

SDHB Forward

GCAGGCTTATCGCTGGATGA

SDHB Reverse

CTGGATTCAGACCCTTGGGG

ERK1 Forward

GCCCGAAACTACCTACAGTC

ERK1 Reverse

CTCAGCCACTGGTTCATCTG

ERK2 Forward

GATCTTAAATTGGTCAGGACAAGG

ERK2 Reverse

CCAACAGATGGCGTGTAAGT

NGAL Forward

GACTACGACCAGTTTGCCAT

NGAL Reverse

CCCCTTGGTTCTTCCGTACA

KIM1 Forward

GTGCTATTTTACCCAGGAGGA

KIM1 Reverse

GGACTTGTGGGAATTTCTGGTTTA

Nrf2 Forward

TGTAGATGACCATGAGTCGC
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Nrf2 Reverse

TCAGGGGTGGTGAAGACTGA
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Results

3.1 STS-supplemented serum free media improves renal
tubular epithelial cell survival in a dose-dependent
manner during cold hypoxia and reoxygenation
Flow cytometry analysis after staining for apoptosis and necrosis showed that NRK-52E
cells treated with SF during in vitro cold IRI exhibited significantly decreased cellular
viability (p < 0.05) compared to control (normoxic) cells. A dose-dependent increase in the
percentage of unstained viable cells was evident as the concentration of STS added to
serum free media was increased (Figure 4A and 4B). While all the experimental samples
exhibited lower renal tubular epithelial cell viability (p < 0.05) than cells grown in
normoxic conditions, cells treated with SF supplemented with 150µM and 500µM STS
exhibited significantly higher viability levels (p < 0.05) to 77 +/- 3% and 78 +/ 6%
compared to serum free only treated cells whose viability levels remained at 41 +/- 8%
(Figure 4B). The reverse trend was observed with apoptosis levels, where cells treated with
SF supplemented with 150µM and 500µM STS exhibited significantly lower apoptosis
levels (p < 0.05) to 26 +/- 3% and 24 +/ 7% compared to serum free only treated cells
whose apoptosis levels remained at 57 +/- 9% (Figure 4C). Additionally, the dosedependent increase in viability and decrease in apoptosis appear to reach optimum levels
with 150µM STS and the addition of higher doses of STS begins to reverse these trends
(Figure 4B and 4C).
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Figure 4: STS supplementation improves renal tubular epithelial cell survival in a
dose-dependent manner during a model of cold ischemia reperfusion injury (IRI).
Cellular viability levels of rat kidney epithelial (NRK-52E; ATCC) cells following cold
IRI. Control cells (Control: Serum Media) were cultured in DMEM containing 10% FBS
and 1% P/S at normal growth conditions of 370C, 21% O2, and 5% CO2. Experimental cells
were treated with either DMEM without FBS (SF alone), SF supplemented with 200nm
AP39 or SF supplemented with different concentrations of STS. The experimental cells
were exposed to cold (100C) hypoxia for 24h, followed by reoxygenation for 24h in
conditions identical to control cells. Following reoxygenation, cells were stained with 7AAD and FITC-Annexin-V for flow cytometry to quantify necrosis and apoptosis
respectively. All data were analyzed using FlowJo V11. (A) Representative images of flow
cytometry results. (B) Mean cell viability % (n=5) as determined by ratio of cells negative
for 7-AAD and FITC-Annexin-V staining. (C) Mean apoptosis % (n=5) determined by
ratio of cells stained positive for FITC-Annexin-V and negative for 7-AAD. Bars indicate
mean ± SEM. Means were analyzed using one-way ANOVA and Tukey’s post-hoc test. *
P < 0.05 vs SF only, † P < 0.05 vs Serum Media. ANOVA, analysis of variance; STS,
sodium thiosulfate; SF, serum free media.
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3.2 STS treatment improves early graft survival and
function
To understand the protective potential of STS against cold IRI in vivo, we injected 150µM
STS into UW solution during cold storage before undergoing rat renal transplantation.
Animals that received grafts treated with STS during 24h cold storage exhibited
significantly improved survival (p < 0.05) compared to those receiving UW-treated grafts,
particularly in the first 3 days (Figure 5A). While UW-treated animals exhibited only
12.5% survival at POD 3, STS-treated animals exhibited 83% survival at POD 3 and still
maintained the same survival rate by the end of the 14-day time course (Figure 5A). Blood
and urine samples were collected on days 3, 5, 7, 10, and 14. STS treatment markedly
improved graft function during the early post-transplant period compared to UW treatment.
Both treatment groups exhibited significantly increased serum creatinine levels (p < 0.05)
at POD 3 compared to Sham (Figure 5B). STS-treated animals showed a decline in serum
creatinine levels to 219µmol/L compared to UW-treated animals whose serum creatinine
remained at 442µmol (p<0.05) on POD 3. Interestingly, the serum creatinine level of STStreated animals decreased towards baseline (Sham) until time of sacrifice at day 14, when
it was comparable to that of Sham (Figure 5B). Both treatment groups exhibited
significantly increase blood urea nitrogen levels (p < 0.05) at POD 3 compared to Sham
(Figure 5C). STS-treated animals showed a decline in blood urea nitrogen levels to 56
mmol/L /L compared to UW-treated animals whose blood urea nitrogen level remained at
106 mmol/L (p<0.05) on POD 3. . Notably, the blood urea nitrogen level of STS-treated
animals decreased towards baseline (Sham) until time of sacrifice at day 14, when it was
comparable to that of Sham at POD 7 and onwards (Figure 5C).
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Figure 5: STS improves renal graft survival and function following 24h cold organ
storage and syngeneic renal transplantation. Survival rates (A) of renal transplant
recipients receiving donor kidneys perfused and stored in UW solution only (UW; black
dashed line) or UW solution plus 150uM STS (STS; blue line) as well as Sham-operated
rats (Sham; black line). UW (n=8), UW+STS (n=6), Sham (n=5). Serum creatinine levels
(B) and blood urea nitrogen levels (C) of renal transplant recipients receiving donor
kidneys perfused and stored in UW solution only (UW; black diamond) or UW solution
plus 150uM STS (UW+STS; white triangle) as well as Sham-operated rats (Sham; gray
circle). Survival data analyzed via Kaplan-Meier survival analysis and log rank test. Serum
creatinine and BUN data analyzed via one-way ANOVA and Tukey’s post-hoc test. Lines
indicate mean serum creatinine and BUN. Note: only one UW rat survived to day 14.
*p<0.05 vs UW, †p<0.05 vs Sham. ANOVA, analysis of variance; STS, sodium
thiosulfate; UW, University of Wisconsin.
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3.3 STS supplementation improves urine osmolality and
induces diuresis after renal transplantation
To investigate the role of STS in total urine output and urine concentration, urine was
collected on days 3, 5, 7, 10, and 14 after a cold IRI renal transplantation model in vivo.
Both treatment groups UW and STS exhibited significantly decreased urine osmolality (p
< 0.05) at POD 3 compared to Sham (Figure 6A). Animals that received grafts treated with
STS during 24h cold storage exhibited urine osmolality levels that increased towards
baseline (Sham) until time of sacrifice on day 14, although it was still statistically
significant compared to Sham. STS led to an increase in urine output from 10 +/- 1mL to
32 +/- 5mL, 23 +/- 4mL, and 17 +/- 5mL following transplantation (p<0.05) during the first
three collection periods compared with Sham-operated rats (Figure 6B). Interestingly, the
mean urine output of STS-treated animals decreased towards baseline (Sham) until time of
sacrifice at day 14, when it was comparable to that of Sham (Figure 6B).
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Figure 6: STS supplementation improves urine osmolality and induces diuresis after
renal transplantation. Urine osmolality levels (A) of renal transplant recipients after
receiving donor kidneys perfused and stored in UW solution only (UW: black diamond) or
UW solution plus 150uM STS (UW+STS: white triangle). Osmolality levels were
measured using the Model 3320 Osmometer and normalized to company provided
standards. Red dash line indicates mean Sham osmolality levels. Urine output levels (B) of
renal transplant recipients after receiving donor kidneys perfused and stored in UW
solution plus 150uM STS (UW+STS: white triangle) and sham-operated rats (Sham: gray
circle). Urine outputs were measured through use of metabolic cages. Note: only one UW
rat (UW: black diamond) survived to day 14 and produced urine. Values are mean (SEM).
† P < 0.05 vs Sham. STS, sodium thiosulfate; UW, University of Wisconsin.
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3.4 STS treatment mitigates donor kidney apoptosis and
necrosis after renal transplantation
Renal sections obtained at POD 3 and 14 were stained with TUNEL as a measure of
apoptotic cell death and scored by a blinded pathologist (Figure 7A). It was revealed that
while UW-treated grafts exhibited significantly elevated (p< 0.05) levels of apoptosis as
indicated by higher TUNNEL score compared to Sham at POD 3, apoptosis level in
UW+STS kidneys were not significantly different compared to Sham at the same time point
and at POD 14 (Figure 7B). In addition, UW+STS grafts exhibited significantly decreased
(p < 0.05) apoptosis levels to 5% compared to UW-treated grafts whose apoptosis levels
remained at 24% following transplantation at POD 3 (Figure 7B).
Renal sections obtained at POD 3 and 14 were stained with H&E and showed that
UW+STS grafts exhibited decreased ATN scores at POD 3 (p < 0.05) compared to UW
(Figure 8). Both treatment groups showed significantly increased ATN scores (p < 0.05) at
POD 3 compared to Sham (Figure 8). Also, whereas only one recipient of UW grafts
survived to POD 14, and hence their ATN scores could not be determined on POD 14,
those of UW+STS grafts survived on POD 14 but showed significantly increased ATN
scores compared to Sham group (Figure 8; p<0.05).

35

Figure 7: STS mitigates renal graft apoptosis after 24h cold organ storage and
syngeneic renal transplantation. (A) Representative images show apoptosis in renal graft
sections stored in UW only and UW + 150uM STS for 24 hours at 4C, and sham operated
sections. Brown areas indicate fragmented DNA; 10x magnification. (B) Corresponding
digital analysis show percent area of sections positive for TUNEL. Threshold limits were
0 lower/130 upper bytes. Sections were obtained at POD 3 (UW, n=5; UW+STS, n=5;
Sham, n=5) and at POD 14 (UW, n=1; UW+STS, n=5; Sham, n=5). Line indicates mean
TUNEL % area. * P < 0.05 vs UW day 3, † P < 0.05 vs Sham day 3. POD, postoperative
day; STS, sodium thiosulfate; TUNEL, terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling; UW, University of Wisconsin.
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Figure 8: STS mitigates renal graft necrosis scores after 24h cold organ storage and
syngeneic renal transplantation. Representative graph show ATN in renal graft sections
stored in UW only and UW + 150uM STS for 24 hours at 4C, and sham operated sections.
ATN scores were assigned to H&E sections, including 0 - 0% graft ATN, 1 – less than
10%, 2 – 11% to 25%, 3 – 26% to 45%, 4 – 46% to 75%, and 5 – greater than 75%. Sections
were obtained at POD 3 (UW, n=5; UW+STS, n=5; Sham, n=5) and at POD 14 (UW, n=1;
UW+STS, n=5; Sham, n=5). Line indicates mean H&E score. * p < 0.05 vs UW day 3, †
p < 0.05 vs Sham POD 3. ATN, acute tubular necrosis; POD, postoperative day; STS,
sodium thiosulfate; UW, University of Wisconsin.
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3.5 STS treated kidneys exhibited decreased injury
markers and inflammatory infiltrate after renal
transplantation
To determine the effect of STS treatment on renal graft injury, renal sections obtained at
POD 3 and 14 were stained with kidney injury molecule-1 (KIM-1) (Figure 9A) to detect
proximal tubular injury and revealed that while UW-treated grafts exhibited significantly
elevated (p < 0.05) levels of KIM-1 expression compared to Sham at POD 3, KIM-1
expression level in STS-treated kidneys were not significantly different compared to Sham
at the same time point and at day 14 (Figure 9B). In addition, STS-treated grafts exhibited
significantly decreased (p < 0.05) KIM-1 levels to 3% compared to UW-treated grafts
whose KIM-1 levels remained at 21% following transplantation at POD 3 (Figure 9B).
Renal grafts obtained at POD 3 and 14 were immunohistochemically stained with
antibodies against macrophage marker CD68 (Figure 10A) and neutrophil marker
myeloperoxidase (MPO) (Figure 11A). UW-treated grafts exhibited significantly increased
(p < 0.05) numbers of both CD68-positive and MPO-positive cells compared with Shamoperated rats at POD 3, while STS-treated grafts showed significantly fewer (p < 0.05)
numbers of CD68-positive and MPO-positive cells at day 3 post transplantation, compared
with UW-treated grafts (Figure 10B and 11B). STS led to a decrease in CD68 area stain
from 20% to 4% and a decrease in MPO area stain from 18% to 3% following
transplantation on POD 3.
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Figure 9: STS mitigates renal graft expression of KIM-1 after 24h cold organ storage
and

syngeneic

renal

transplantation.

Representative

images

(A)

show

immunohistochemical staining for renal biomarker of injury KIM-1 (brown areas) of renal
graft sections stored in UW only and UW + 150uM STS for 24 hours at 4C, and sham
operated sections; 10x magnification. (B) Corresponding digital analysis show percent area
of sections positive for KIM-1. Threshold limits were 0 lower/110 upper bytes. Sections
were obtained at POD 3 (UW, n=5; UW+STS, n=5; Sham, n=5) and at POD 14 (UW, n=1;
UW+STS, n=5; Sham, n=5). Line indicates mean KIM-1 % area. * P < 0.05 vs UW day 3,
† P < 0.05 vs Sham day 3. POD, postoperative day; STS, sodium thiosulfate; UW,
University of Wisconsin.
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Figure 10: STS decreases macrophage infiltrate in renal grafts after 24-hour cold
organ storage and syngeneic renal transplantation. Representative images (A) show
immunohistochemical staining for macrophage marker CD68 of renal graft sections stored
in UW only and UW + 150uM STS for 24 hours at 4C, and sham operated sections; 10x
magnification. (B) Corresponding digital analysis show percent area of sections positive
for CD68. Threshold limits were 0 lower/110 upper bytes. Sections were obtained at POD
3 (UW, n=5; UW+STS, n=5; Sham, n=5) and at POD 14 (UW, n=1; UW+STS, n=5; Sham,
n=5). Line indicates mean CD68 % area. * P < 0.05 vs UW day 3, † P < 0.05 vs Sham day
3. POD, postoperative day; STS, sodium thiosulfate; UW, University of Wisconsin.
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Figure 11: STS decreases neutrophil infiltrate in renal grafts after 24-hour cold organ
storage and syngeneic renal transplantation. Representative images (A) show
immunohistochemical staining for macrophage marker MPO of renal graft sections stored
in UW only and UW + 150uM STS for 24 hours at 4C, and sham operated sections; 10x
magnification. (B) Corresponding digital analysis show percent area of sections positive
for MPO. Threshold limits were 0 lower/110 upper bytes. Sections were obtained at POD
3 (UW, n=5; UW+STS, n=5; Sham, n=5) and at POD 14 (UW, n=1; UW+STS, n=5; Sham,
n=5). Line indicates mean MPO % area. * P < 0.05 vs UW day 3, † P < 0.05 vs Sham day
3. POD, postoperative day; STS, sodium thiosulfate; UW, University of Wisconsin.
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3.6 STS treated grafts modified renal expression of proinflammatory, pro-apoptotic, and mitochondrial markers
Renal expression of pro-inflammatory, pro-apoptotic, mitochondria targeted, and kidney
injury markers was determined via qRT-PCR on kidneys obtained at day 3 posttransplantation. Genes were normalized against beta-actin and fold changes of gene
expression were compared with Sham-operated rats. Expression of pro-inflammatory
genes PARP, IFN-y, TNF-α and IL-6 were markedly decreased in STS-treated grafts, with
IFN-y, TNF-α and IL-6 expression being significantly decreased compared with UWtreated grafts (p< 0.05, Figure 12A). Relative expression of anti-apoptotic Bcl-2 was
markedly increased in the STS group compared with that in the UW group, although this
increase did not reach statistical significance (Figure 12A). Expression of pro-apoptotic
genes BAX, caspase 3, BID, JNK1, and JNK2 were markedly decreased in STS-treated
grafts, with BAX, caspase 3, and JNK2 expression being significantly decreased compared
with UW-treated grafts (p< 0.05, Figure 12A). Expression of mitochondria genes
peroxisome proliferator-activated receptor gamma coactivator (PGC) 1α, NDUFB8
(complex I), SDHB (complex II), and nuclear factor erythroid 2-related factor 2 (Nrf2) in
STS-treated grafts were significantly increased compared with UW-treated grafts (p < 0.05,
Figure 12B). Expression of anti-apoptotic genes ERK1 and ERK2 in STS-treated grafts
were significantly increased compared with UW-treated grafts (p < 0.05, Figure 12B).
Expression of kidney injury molecule KIM-1 in STS-treated grafts were significantly
decreased compared with UW-treated grafts (p < 0.05, Figure 12C). Relative expression of
kidney injury marker NGAL showed a decreasing trend in the STS group compared with
that in the UW group, although this decrease did not reach statistical significance (Figure
12C).
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Figure 12: STS modulates renal graft expression of inflammatory and apoptotic
genes. qPCR analysis of renal graft homogenates for expression levels of (A) proinflammatory genes (PARP, IFN-y, TNF-a, and IL-6), anti-apoptotic genes (Bcl-2, ERK1,
and ERK2), pro-apoptotic genes (BAX, caspase-3, BID, JNK1/2), (B) mitochondrial genes
(PGC-a, complex I, complex II, Nrf2) (C) and kidney injury markers (NGAL, KIM-1).
Genes were normalized against beta-actin and fold changes of gene expression were
compared with Sham-operated rats. Renal grafts were perfused and stored in UW solution
only (UW) or UW solution plus 150uM STS (UW+STS) and obtained at post-operative
day 3. Values are mean log2 fold change (SD). * p < 0.05 vs UW POD 3. POD,
postoperative day; qPCR, quantitative polymerase chain reaction; STS, sodium thiosulfate;
UW, University of Wisconsin.
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Chapter 4

4

Discussion
When prolonged, ischemia reperfusion injury (IRI) is a substantial concern because

renal IRI has been associated with acute graft rejection, delayed graft function, and early
graft loss following renal transplantation [8,9]. This study establishes supplementation of
standard preservation solution with sodium thiosulfate (STS), a clinically viable FDAapproved H2S donor, to mitigate transplant-induced cold renal IRI, improve graft function
and prolong graft survival. Using an in vitro model of renal IRI and rat model of syngeneic
orthotopic kidney transplantation, we demonstrate for the first time that supplementation
of University of Wisconsin (UW) solution with STS during prolonged cold storage is cytoand organ protective.
The primary findings in our in vitro model are that STS supplementation to serum
free media protects renal epithelial cells from cold hypoxia and warm reoxygenationinduced apoptosis in a dose dependent manner (Figure 3A). Our findings were in
agreement with previous studies where they showed the protective effects of the
mitochondria-targeting H2S donor drug, AP39, in an in vitro model of cold IRI [19].
Interestingly, a higher STS concentration of 1mM reversed the beneficial effects, implying
that STS exhibits a biphasic dose-response phenomenon referred to as hormesis, in which
a higher concentration is cytotoxic while a lower concentration is cytoprotective.
Mitochondrial damage is a major consequence of renal IRI, as mitochondrial permeability
can inhibit ATP production and increase ROS production, a devastating mediator of tissue
injury [110]. It has been recently suggested that mitochondria are a primary site of STS
activity. Not only is STS known to generate H2S in the mitochondria via glutathionedependent reduction and vice versa via the sulfide oxidation pathway, recent studies have
shown that STS can preserve mitochondrial ATP synthesis, decrease ROS production, and
improve ETC complex enzyme activities [80,84,96,103]. In addition, recent studies
showed that STS significantly increased the expression of PGC-1α, a positive regulator of
mitochondrial biogenesis and ATP production [77, 104]. The improved mitochondrial
enzyme activity and antioxidant protectiveness was supported by an increased expression
of PGC-1α in the rat hearts treated with STS, compared to non-treated hearts [104]. These
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findings are consistent with our qPCR results, which showed that STS treated grafts had
significantly elevated expression of PGC-1α compared to UW grafts. Interestingly, both
STS and PGC-1α can activate nuclear factor erythroid-related factor 2 (Nrf2), a
transcription factor known to have antioxidant characteristics [77, 111]. Under normal
circumstances, Keap1 proteins captures Nrf2 and holds it in the cytoplasm [111]. However,
the reactive sulfur atom of STS triggers a sulfhydration reaction and forces Keap1 to
undergo a structural change, leading to the release of Nrf2 and its translocation into the
nucleus in order to bind to antioxidant response elements (ARE) to induce expression of
numerous antioxidant gene clusters [112-114]. The elevated antioxidants are responsible
for protecting against lipid peroxidation and maintaining redox balance [115]. Therefore,
Nrf2 can be considered as a negative regulator of ferroptosis and promoter of resistance
against ferroptotic cell death. These findings reflect our qPCR results, where STS-treated
grafts exhibited significantly elevated expression of Nrf2 compared to UW grafts. These
observations may be the reason why STS treated grafts had significantly increased
expression of mitochondrial ETC complex I- II as well has increased graft survival and
function compared to UW grafts. Overall, these results show that STS therapy is effective
against cold IRI in vitro, which may be due to its numerous protective characteristics of
mitigating ROS, enabling mitochondrial biogenesis and mitigating cellular apoptosis.
Based on the in vitro results, we decided to investigate the effects of STS in an in
vivo murine model of cold renal syngeneic transplantation-associated IRI. Our findings
show, for the first time, that treatment of donor kidneys with STS during prolonged cold
(40C) storage significantly improved graft function, shown by decreased serum creatinine
and blood urea nitrogen (BUN) levels, higher urine output and prolonged recipient survival
compared to kidneys stored in UW solution alone. The observed improvement in renal
function after transplantation of grafts preserved in STS-supplemented UW solution
conferred a significant survival advantage. Quantitatively, STS treatment prolonged the
life of the graft such that 83% of STS treated animals survived from POD 6 and onwards
compared to only 12.5% of UW treated animals. Our model of renal transplantation IRI
involved an extreme (24 hours) period of cold ischemia, which previous studies have
shown to be associated with a survival rate of 14% when stored in UW solution alone and
is shown by the observation that only one UW animal in our study survived until POD 14

45

[62]. Our study showing that STS increases renal graft survival after an extreme period of
cold organ storage when UW solution alone was not sufficient to preserve the graft organ,
is an important clinical observation. The length of cold IRI is proportional to the incidence
of DGF as well as decreased long-term graft survival [35]. Considering that previous
studies have shown that the risk for DGF rose significantly for donor kidneys experiencing
>22 hours of cold ischemia, the consequences of lengthy cold storage time on renal graft
survival and function are a real clinical concern [116]. It is important to note that the
immediacy of urine output after clinical transplantation is a critical outcome which
determines whether dialysis is required to address delayed graft function (DGF). Thus, our
findings that STS increases urine output immediately after transplantation that is
comparable to the Sham group on POD 14 is a promising finding. Thus, the future benefit
of adding STS to preservation solutions may present a potential solution to this ongoing
issue.
Histological staining studies showed that STS treatment significantly decreased
apoptosis and acute tubular necrosis (ATN) compared with UW treatment alone, which is
likely a mechanism by which STS improves graft survival and function. We also found
that STS treatment significantly improved the up-regulation in renal graft expression of the
anti-apoptotic gene ERK1/2 and significantly decreased expression of pro-apoptotic gene
BAX, caspase 3, and JNK2. This observation may explain the decreased levels of apoptosis
in STS-treated renal grafts compared to UW treated grafts observed via TUNEL staining.
Our findings also concur with recent evidence that showed how STS treatment can
counteract multiple pro-apoptotic mechanisms. Mechanistically, STS can inactivate
caspase-3 by preventing access of natural substrate to the active site by attaching to the
active site of caspase-3 via strong hydrogen bonds, ultimately halting apoptosis [106]. STS
also inhibits phosphorylation of JNK, a protein that is upregulated by inflammatory
cytokines plays a critical role in apoptotic signaling [112]. Although it was not statistically
significant, treatment with STS slightly reduced pro-apoptotic genes BID and JNK1 and
slightly mitigated anti-apoptotic gene BCL-2. A recent study by Chou et al. investigated
the role of STS on renal apoptosis-related mechanism and found that STS treatment
significantly reduced renal BAX expression compared to the non-treatment group, which
aligns with our findings [117]. Interestingly, the renal Bcl-2 expression in STS treatment
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group had an elevated trend compared to non-treatment group, which also supports our
finding [117]. Other studies showed that STS treatment prevented the reduction of Bcl-2
compared to non-treatment groups and could also elevate Bcl-2 expression via activation
of Nrf2-dependent signaling, contrasting our observations [106, 112]. This discrepancy
may be attributed to insufficient time for the modulation of Bcl-2 transcription to show as
increased protein translation prior to analyzing it. Further immunohistochemical analysis
of renal graft injury showed that STS reduced expression of KIM-1, an important
biomarker that provide additional sensitive assessment of early renal injury along with
apoptosis and ATN [118, 119]. This observation also concurs with our findings of
significantly decreased expression of KIM-1 in STS treated grafts compared to UW grafts.
Being a type 1 transmembrane protein, KIM-1 expression level is significantly elevated in
the proximal tubule in patients with post-ischemic kidney [120, 121]. Mechanistically,
ischemia initiates phosphorylation and translocation of STAT3 to the nucleus, which binds
to the KIM-1 promoter and elevates its mRNA and protein levels [118, 122]. During cold
IRI, the KIM-1 ectodomain, which is comprised of an immunoglobulin and a mucin
domain, sheds and is subsequently secreted into the urine and blood [121]. In a recent study
by Han et al., they showed that ischemic ATN was the most common predisposing factor
for elevation of KIM-1 protein [123], which supports our findings that STS-treated kidneys
exhibited lower ATN scores and thus, a lower KIM-1 expression level. Although it was
not statistically significant, grafts treated with STS exhibited slightly reduced expression
of NGAL, another important kidney injury biomarker, compared to UW grafts [124]. These
findings are not surprising as previous studies have shown that decreased levels of KIM-1
and NGAL are associated with less renal graft injury and longer graft survival [124].
As discussed earlier, a potential mechanism by which STS improves graft survival
and function is the reduction of apoptosis and necrosis during cold IRI. A mediator of such
apoptotic and necrotic tissue injury is the subsequent surge in inflammatory cytokines and
activation of immune system [125]. This study found significant reduction in CD68positive macrophages and MPO-positive neutrophils present in STS treated renal grafts
compared to UW grafts as well as significant downregulation of pro-inflammatory genes
IFN-y and TNF- α. These inflammatory cytokines and recruitment of the innate immune
system are known to be mediators of cell death during cold IRI [17], and their reduction in
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UW+STS grafts is likely attributed to the well-known characteristics of STS to decrease
the endothelial permeability in vascular endothelial monolayer, attenuate TNFα-induced
cytokine production, and elicit production of anti-inflammatory cytokines [90]. In addition,
the downregulation of pro-inflammatory gene IL-6 was observed in the STS group relative
to the UW group, which matches the findings of a previous study on the anti-inflammatory
activity of STS by reducing levels of TNF-α and IL-6 in neurological diseases [126, 127].
IL-6 is a key proinflammatory cytokine in its role in acute kidney injury [128], and its
downregulation by STS may contribute to the improved graft survival and function of the
STS treated grafts compared to the UW grafts. A proposed mechanism of how STS exerts
its cytoprotective effects in prolonged cold renal IRI in transplantation is shown in Figure
13.
The in vitro cold renal IRI model is a relevant model to investigate the protective
effects of STS-supplemented UW solution during hypoxic storage, followed by reperfusion
[129]. The use of this model allowed us to induce a hypoxic (0.05% O2) environment with
the use of a hypoxic chamber (HypOxystation H85, USA) for 24 hours to mimic a
prolonged cold storage time that we might see clinically today. A major limitation of this
model is that the temperature of cold storage is 100C, whereas the current standard
preservation method for SCS utilizes 40C [34]. However, 100C was the lowest temperature
that could be technologically achieved without jeopardizing the hypoxic environment. A
potential solution is to use chemically induced hypoxia in a plastic bag and place it in a
40C fridge in order to reflect clinical settings of SCS. However, these anaerobic atmosphere
generation bags were designed to be used at warm temperatures (210C-370C) since the
chemical compounds that induce the hypoxic environment functions under that condition
[130]. Future studies will be aimed at optimizing the temperature in the hypoxia chamber
to mimic clinical SCS settings. Achieving a consistent temperature of 40C without
sacrificing a hypoxic environment will allow us to determine whether the observed
phenotypes in the experimental in vitro cold IRI model are consistently expressed. Another
limitation to this model was adding STS to serum free (SF) media for treating cold
ischemia, which does not reflect the current gold standard preservation solution for SCS of
kidneys: UW solution [48]. Interestingly, other studies with a similar in vitro model of SCS
against renal IRI also chose to utilize other solutions for preservation, such as SF or PBS
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Figure 13: Proposed mechanism of action of STS in prolonged cold renal IRI in
transplantation. Thiosulfate (S2O32-) is produced from hydrogen sulfide (H2S) via the
sulfide oxidation pathway. We propose that thiosulfate acts by attenuating inflammatory
cytokines and pro-inflammatory genes, leading to decreased recruitment of innate immune
system. Thiosulfate also increase expression of PGC-1α, a positive regulator of
mitochondrial biogenesis and ATP production. Nuclear translocation of phosphorylated
Nrf2 binds ARE and promotes expression of anti-apoptotic and antioxidative genes,
ultimately leading to decreased ROS production and cell injury.
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[62]. This could be due to the irony that UW solution is doing its protective job too well
during SCS against renal IRI, thus it’s hard to display a change in cell viability from
treatment groups vs. non-treatment groups. In addition to measuring apoptosis and necrosis
with flow cytometry, future studies will use JC-1, a stain that quantifies mitochondrial
membrane permeability [131] since mitochondrial dysfunction is an fundamental part of
renal IRI.
The rat in vivo model of cold IRI is a a relevant model to investigate the protective
effects of STS on kidney survival and function following renal transplantation. It mimics
a human kidney donor-recipient transplantation in a clinical setting and allows us to
analyze urine and blood data. However, a drawback is that our model involves syngeneic
transplantation, meaning that the donor and recipient rats are genetically identical and are
thus, immunologically compatible as to allow for transplantation. This syngeneic concept
only applies to identical twins, whereas most of the renal transplantations that are done
clinically have the donor and recipient being genetically different. This forces patients to
undergo immunological tests prior to transplantation to identify the donor’s HLA antigens
and determine if the donor and recipient are compatible [132]. These tests are done to avoid
the recruitment of both the innate and adaptive recipient immune response against the
kidney allograft due to mismatched antigens present on donor tissue, ultimately resulting
in increased graft injury and lowered graft survival compared to syngeneic transplantation
[133]. Future studies will be aimed at determining the effect of STS on an in vivo cold IRI
model of renal allogeneic transplantation. Another limitation to this model was the duration
of SCS being 24 hours, which represented a prolonged cold IRI period reflecting the organ
being transported from one transplant center to another. On the other hand, if the living
donor and recipient were in the same building, the cold storage time would be diminished
to 4-6 hours. Thus, future studies should explore the protective effects of STS on cold renal
IRI with various timepoints for SCS prior to transplanting the kidney in the recipient to
mimic clinical settings. Finally, another limitation in this model is that it only focused on
living donors, whereas in the clinical setting sub-optimal grafts from donation after cardiac
death (DCD) donors are being accepted for usage more frequently to increase the supply
of donor kidneys [134]. DCD donors exposes donor organs to various periods of warm
ischemia in addition to cold ischemia times during SCS and is associated with increased
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rates of delayed graft function (DGF) and decreased graft survival compared to living
donors [2]. Future studies will be aimed at incorporating a warm ischemic time in the in
vivo rat kidney transplantation model to assess STS on treating DCD kidneys that are more
susceptible to damage associated with IRI.
In conclusion, our results show a novel discovery which demonstrates that
supplementation of standard preservation solution with a clinically viable H2S donor drug
during prolonged SCS of renal grafts protects against transplant-induced cold renal IRI.
We have shown that STS treatment improves overall graft quality and graft function and
prolongs transplant recipient survival. Furthermore, these protective effects of STS appear
to be mitochondria-targeted and mediated by antioxidant, anti-apoptotic, and antiinflammatory mechanisms. Considering that the risk of DGF increases with prolonged cold
ischemic time in clinical kidney transplantation, which raises a major clinical concern, the
discovery that STS protects renal grafts during prolonged SCS and prevents DGF after
transplantation provides a great clinical promise that could decrease or prevent the
incidence of DGF in clinical kidney transplantation. Thus, the future benefit of adding STS
to preservation solutions may present a potential solution to this ongoing issue. Overall,
this study adds to the growing body of literature that supports the cytoprotective effects of
STS against organ IRI, particularly improving graft outcomes in prolonged transplantinduced cold kidney IRI. These strategies could facilitate the use of more grafts exposed to
prolonged cold ischemic times, which could increase the pool of transplantable organs.
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Appendices
Appendix A 1: STS helps improve early renal graft function and decreases apoptosis
and inflammation following prolonged SCS and kidney transplantation.

Supplemental Figure 1: STS helps improve early renal graft function and decreases
apoptosis and inflammation following prolonged SCS and kidney transplantation.
Summary of data containing urine, blood, and graft sections obtained on POD 3. Serum
creatinine and blood urea nitrogen (BUN) levels were obtained from blood on day 3.
Kidney sections obtained on day 3 were stained with TUNEL, H&E, KIM-1, CD68, and
MPO to measure apoptosis, necrosis, and inflammation respectively. Data are mean ±
SEM. * p < 0.05 vs UW day 3, † p < 0.05 vs Sham POD 3.
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